Viewing Study NCT02393950

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 5:18 PM

Ignite Modification Date: 2026-01-23 @ 2:11 PM

Study NCT ID: NCT02393950

Status: COMPLETED

Last Update Posted: 2016-12-23

First Post: 2015-03-06

Is Gene Therapy: True

Has Adverse Events: True

Brief Title: Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers

Sponsor:

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Raw JSON

{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'clinicaltrials@orionpharma.com', 'phone': '+358104261', 'title': 'Clinical Trials Information Desk', 'organization': 'Orion Corporation'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'From the start of study treatment until the end of study visit (approximately 12-16 weeks)', 'description': '16 subjects were randomised into 2 panels of 8 subjects. Each panel of 8 subjects participated in 4 periods as a crossover, during each period 6 subjects received active and 2 subjects received placebo, There was a 2 week washout between each period.', 'eventGroups': [{'id': 'EG000', 'title': 'ODM-106 Capsule B 2mg', 'description': 'Single oral dose 2 x 1 mg ODM-106 Capsule B', 'otherNumAtRisk': 6, 'otherNumAffected': 0, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'ODM-106 Capsule B 10mg', 'description': 'Single oral dose 2 x 5 mg ODM-106 Capsule B', 'otherNumAtRisk': 6, 'otherNumAffected': 4, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'ODM-106 Capsule B 25mg', 'description': 'Single oral dose 2 x 10 mg 1 x 5 mg ODM-106 Capsule B', 'otherNumAtRisk': 6, 'otherNumAffected': 5, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'ODM-106 Capsule B 50mg', 'description': 'Single oral dose 5 x 10 mg ODM-106 Capsule B', 'otherNumAtRisk': 6, 'otherNumAffected': 1, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'ODM-106 Capsule B 100mg (1 x 100mg)', 'description': 'Single oral dose 1 x 100 mg ODM-106 Capsule B', 'otherNumAtRisk': 6, 'otherNumAffected': 2, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'ODM-106 Capsule B 100mg (10 x 10mg)', 'description': 'Single oral dose 10 x 10 mg ODM-106 Capsule B', 'otherNumAtRisk': 6, 'otherNumAffected': 1, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG006', 'title': 'ODM-106 Capsule B 200mg', 'description': 'Single oral dose 20 x 10 mg ODM-106 Capsule B', 'otherNumAtRisk': 6, 'otherNumAffected': 3, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG007', 'title': 'ODM-106 Capsule A 100mg', 'description': 'Single oral dose 10 x 10 mg ODM-106 Capsule A', 'otherNumAtRisk': 6, 'otherNumAffected': 2, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG008', 'title': 'Placebo', 'description': '2 placebo subjects per Arm with matched number of placebo capsules', 'otherNumAtRisk': 16, 'otherNumAffected': 3, 'seriousNumAtRisk': 16, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'SUNBURN', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'RHYTHM IDIOVENTRICULAR', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'VENTRICULAR EXTRASYSTOLES', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'EPISTAXIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'NASAL DRYNESS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'OROPHARYNGEAL PAIN', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'PRODUCTIVE COUGH', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'DISTURBANCE IN ATTENTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'DYSGEUSIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'HEADACHE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'EAR DISCOMFORT', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'DIARRHOEA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'NAUSEA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'HYPERHIDROSIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'RASH', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'MYALGIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'ABCESS LIMB', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'GASTROENTERITIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'NASAL HERPES', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'NASOPHARYNGITIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'RHINITIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}, {'term': 'URINARY TRACT INFECTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedRA 18.1'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '16', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'ODM-106 Capsule B 2mg', 'description': 'Single oral dose 2 x 1 mg ODM-106 Capsule B'}, {'id': 'OG001', 'title': 'ODM-106 Capsule B 10mg', 'description': 'Single oral dose 2 x 5 mg ODM-106 Capsule B'}, {'id': 'OG002', 'title': 'ODM-106 Capsule B 25mg', 'description': 'Single oral dose 2 x 10mg 1 x 5 mg ODM-106 Capsule B'}, {'id': 'OG003', 'title': 'ODM-106 Capsule B 50mg', 'description': 'Single oral dose 5 x 10mg ODM-106 Capsule B'}, {'id': 'OG004', 'title': 'ODM-106 Capsule B 100mg (1 x 100mg)', 'description': 'Single oral dose 1 x 100mg ODM-106 Capsule B'}, {'id': 'OG005', 'title': 'ODM-106 Capsule B 100mg (10 x 10mg)', 'description': 'Single oral dose 10 x 10mg ODM-106 Capsule B'}, {'id': 'OG006', 'title': 'ODM-106 Capsule B 200mg', 'description': 'Single oral dose 20 x 10mg ODM-106 Capsule B'}, {'id': 'OG007', 'title': 'ODM-106 Capsule A 100mg', 'description': 'Single oral dose 10 x 10mg ODM-106 Capsule A'}, {'id': 'OG008', 'title': 'Placebo', 'description': '2 placebo subjects per Arm with matched number of placebo capsules.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}, {'value': '3', 'groupId': 'OG008'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From screening up to 16 weeks', 'description': 'Clinically relevant changes from baseline in safety laboratory assessments (haematology, clinical chemistry, urinalysis), vital signs (pulse and heart rate), 12 lead electrocardiograms, Holter electrocardiograms, telemetry, physical examination.', 'unitOfMeasure': 'subjects affected', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Plasma Concentration (cMax) of ODM-106', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'ODM-106 Capsule B 2mg', 'description': 'Single oral dose 2 x 1 mg ODM-106 Capsule B'}, {'id': 'OG001', 'title': 'ODM-106 Capsule B 10mg', 'description': 'Single oral dose 2 x 5 mg ODM-106 Capsule B'}, {'id': 'OG002', 'title': 'ODM-106 Capsule B 25mg', 'description': 'Single oral dose 2 x 10 mg and 1 x 5 mg ODM-106 Capsule B'}, {'id': 'OG003', 'title': 'ODM-106 Capsule B 50mg', 'description': 'Single oral dose 5 x 10 mg ODM-106 Capsule B'}, {'id': 'OG004', 'title': 'ODM-106 Capsule B 100mg (1 x 100mg)', 'description': 'Single oral dose 1 x 100 mg ODM-106 Capsule B'}, {'id': 'OG005', 'title': 'ODM-106 Capsule B 100mg (10 x 10mg)', 'description': 'Single oral dose 10 x 10 mg ODM-106 Capsule B'}, {'id': 'OG006', 'title': 'ODM-106 Capsule B 200mg', 'description': 'Single oral dose 20 x 10 mg ODM-106 Capsule B'}, {'id': 'OG007', 'title': 'ODM-106 Capsule A 100mg', 'description': 'Single oral dose 10 x 10 mg ODM-106 Capsule A'}, {'id': 'OG008', 'title': 'Placebo', 'description': '2 placebo subjects per Arm with matched number of placebo capsules.'}], 'classes': [{'categories': [{'measurements': [{'value': '9.1', 'spread': '4.2', 'groupId': 'OG000'}, {'value': '18.4', 'spread': '11.4', 'groupId': 'OG001'}, {'value': '67.8', 'spread': '51.7', 'groupId': 'OG002'}, {'value': '119.2', 'spread': '60.1', 'groupId': 'OG003'}, {'value': '22.0', 'spread': '20.1', 'groupId': 'OG004'}, {'value': '225.9', 'spread': '177.2', 'groupId': 'OG005'}, {'value': '547.7', 'spread': '319.5', 'groupId': 'OG006'}, {'value': '8.3', 'spread': '9.1', 'groupId': 'OG007'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.', 'description': 'cMax of ODM-106 after single dosing of either Capsule B or Capsule A', 'unitOfMeasure': 'ng/ml', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Area Under the Plasma Concentration Versus Time Curve (AUC) of ODM-106', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'ODM-106 Capsule B 2mg', 'description': 'Single oral dose 2 x 1 mg ODM-106 Capsule B'}, {'id': 'OG001', 'title': 'ODM-106 Capsule B 10mg', 'description': 'Single oral dose 2 x 5 mg ODM-106 Capsule B'}, {'id': 'OG002', 'title': 'ODM-106 Capsule B 25mg', 'description': 'Single oral dose 2 x 10 mg and 1 x 5 mg ODM-106 Capsule B'}, {'id': 'OG003', 'title': 'ODM-106 Capsule B 50mg', 'description': 'Single oral dose 5 x 10 mg ODM-106 Capsule B'}, {'id': 'OG004', 'title': 'ODM-106 Capsule B 100mg (1 x 100mg)', 'description': 'Single oral dose 1 x 100 mg ODM-106 Capsule B'}, {'id': 'OG005', 'title': 'ODM-106 Capsule B 100mg (10 x 10mg)', 'description': 'Single oral dose 10 x 10 mg ODM-106 Capsule B'}, {'id': 'OG006', 'title': 'ODM-106 Capsule B 200mg', 'description': 'Single oral dose 20 x 10 mg ODM-106 Capsule B'}, {'id': 'OG007', 'title': 'ODM-106 Capsule A 100mg', 'description': 'Single oral dose 10 x 10 mg ODM-106 Capsule A'}, {'id': 'OG008', 'title': 'Placebo', 'description': '2 placebo subjects per Arm with matched number of placebo capsules.'}], 'classes': [{'categories': [{'measurements': [{'value': '16.9', 'spread': '8.8', 'groupId': 'OG000'}, {'value': '61.3', 'spread': '44.1', 'groupId': 'OG001'}, {'value': '213.8', 'spread': '78.7', 'groupId': 'OG002'}, {'value': '559.4', 'spread': '310.9', 'groupId': 'OG003'}, {'value': '297.4', 'spread': '346.3', 'groupId': 'OG004'}, {'value': '1089.2', 'spread': '977.0', 'groupId': 'OG005'}, {'value': '2850.8', 'spread': '2319.8', 'groupId': 'OG006'}, {'value': '82.0', 'spread': '64.7', 'groupId': 'OG007'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine sampling, pre-dose and for 24 hours post dose at each dose level', 'description': 'AUC of ODM-106 after single oral dosing of either Capsule B or Capsule A.', 'unitOfMeasure': 'h*ng/ml', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Time to Peak Plasma Concentration (Tmax) of ODM-106', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'ODM-106 Capsule B 2mg', 'description': 'Single oral dose 2 x 1 mg ODM-106 Capsule B'}, {'id': 'OG001', 'title': 'ODM-106 Capsule B 10mg', 'description': 'Single oral dose 2 x 5 mg ODM-106 Capsule B'}, {'id': 'OG002', 'title': 'ODM-106 Capsule B 25mg', 'description': 'Single oral dose 2 x 10 mg 1 x 5mg ODM-106 Capsule B'}, {'id': 'OG003', 'title': 'ODM-106 Capsule B 50mg', 'description': 'Single oral dose 5 x 10 mg ODM-106 Capsule B'}, {'id': 'OG004', 'title': 'ODM-106 Capsule B 100mg (1 x 100mg)', 'description': 'Single oral dose 1 x 100 mg ODM-106 Capsule B'}, {'id': 'OG005', 'title': 'ODM-106 Capsule B 100mg (10 x 10mg)', 'description': 'Single oral dose 10 x 10 mg ODM-106 Capsule B.'}, {'id': 'OG006', 'title': 'ODM-106 Capsule B 200mg', 'description': 'Single oral dose 20 x 10 mg ODM-106 Capsule B'}, {'id': 'OG007', 'title': 'ODM-106 Capsule A 100mg', 'description': 'Single oral dose 10 x 10 mg ODM-106 Capsule A.'}, {'id': 'OG008', 'title': 'Placebo', 'description': '2 placebo subjects per Arm with matched number of placebo capsules.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.7', 'groupId': 'OG000', 'lowerLimit': '0.5', 'upperLimit': '1.0'}, {'value': '1.9', 'groupId': 'OG001', 'lowerLimit': '1.5', 'upperLimit': '3.0'}, {'value': '1.5', 'groupId': 'OG002', 'lowerLimit': '0.5', 'upperLimit': '3.0'}, {'value': '2.1', 'groupId': 'OG003', 'lowerLimit': '0.8', 'upperLimit': '3.5'}, {'value': '5.8', 'groupId': 'OG004', 'lowerLimit': '1.5', 'upperLimit': '23.9'}, {'value': '1.5', 'groupId': 'OG005', 'lowerLimit': '0.8', 'upperLimit': '3.5'}, {'value': '1.5', 'groupId': 'OG006', 'lowerLimit': '0.8', 'upperLimit': '3.5'}, {'value': '3.0', 'groupId': 'OG007', 'lowerLimit': '1.5', 'upperLimit': '4.0'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level', 'description': 'tmax of ODM-106 after single oral dosing of Capsule B or Capsule A', 'unitOfMeasure': 'h', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Elimination Half-life of ODM-106', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'ODM-106 Capsule B 2mg', 'description': 'Single oral dose 2 x 1 mg ODM-106 Capsule B.'}, {'id': 'OG001', 'title': 'ODM-106 Capsule B 10mg', 'description': 'Single oral dose 2 x 5 mg ODM-106 Capsule B.'}, {'id': 'OG002', 'title': 'ODM-106 Capsule B 25mg', 'description': 'Single oral dose 2 x 10 mg 1 x 5 mg ODM-106 Capsule B.'}, {'id': 'OG003', 'title': 'ODM-106 Capsule B 50mg', 'description': 'Single oral dose 5 x 10 mg ODM-106 Capsule B.'}, {'id': 'OG004', 'title': 'ODM-106 Capsule B 100mg (1 x 100mg)', 'description': 'Single oral dose 1 x 100 mg ODM-106 Capsule B.'}, {'id': 'OG005', 'title': 'ODM-106 Capsule B 100mg (10 x 10mg)', 'description': 'Single oral dose 10 x 10 mg ODM-106 Capsule B.'}, {'id': 'OG006', 'title': 'ODM-106 Capsule B 200mg', 'description': 'Single oral dose 20 x 10 mg ODM-106 Capsule B.'}, {'id': 'OG007', 'title': 'ODM-106 Capsule A 100mg', 'description': 'Single oral dose 10 x 10 mg ODM-106 Capsule A.'}, {'id': 'OG008', 'title': 'Placebo', 'description': '2 placebo subjects per Arm with matched number of placebo capsules.'}], 'classes': [{'categories': [{'measurements': [{'value': '9.5', 'spread': '5.5', 'groupId': 'OG000'}, {'value': '20.6', 'spread': '12.7', 'groupId': 'OG001'}, {'value': '23.0', 'spread': '2.1', 'groupId': 'OG002'}, {'value': '27.3', 'spread': '4.7', 'groupId': 'OG003'}, {'value': '23.5', 'spread': '6.3', 'groupId': 'OG004'}, {'value': '27.4', 'spread': '9.2', 'groupId': 'OG005'}, {'value': '32.1', 'spread': '10.0', 'groupId': 'OG006'}, {'value': '21.7', 'spread': '3.2', 'groupId': 'OG007'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.', 'description': 'Elimination half-life of ODM-106 after single dosing of either Capsule B or Capsule A', 'unitOfMeasure': 'h', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Metabolite Screening in Plasma and Urine', 'timeFrame': 'Plasma samples at pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine samples, pre-dose and for 24 hours post dose at each dose level', 'description': 'Metabolite screening in plasma and urine after single dosing', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Effect of ODM-106 on Growth Hormone Levels', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '14', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'ODM-106 Capsule B 2mg', 'description': 'Single oral dose 2 x 1 mg ODM-106 Capsule B'}, {'id': 'OG001', 'title': 'ODM-106 Capsule B 10mg', 'description': 'Single oral dose 2 x 5 mg ODM-106 Capsule B'}, {'id': 'OG002', 'title': 'ODM-106 Capsule B 25mg', 'description': 'Single oral dose 2 x 10mg 1 x 5 mg ODM-106 Capsule B'}, {'id': 'OG003', 'title': 'ODM-106 Capsule B 50mg', 'description': 'Single oral dose 5 x 10mg ODM-106 Capsule B'}, {'id': 'OG004', 'title': 'ODM-106 Capsule B 100mg (1 x 100mg)', 'description': 'Single oral dose 1 x 100mg ODM-106 Capsule B'}, {'id': 'OG005', 'title': 'ODM-106 Capsule B 100mg (10 x 10mg)', 'description': 'Single oral dose 10 x 10mg ODM-106 Capsule B'}, {'id': 'OG006', 'title': 'ODM-106 Capsule B 200mg', 'description': 'Single oral dose 20 x 10mg ODM-106 Capsule B'}, {'id': 'OG007', 'title': 'ODM-106 Capsule A 100mg', 'description': 'Single oral dose 10 x 10mg ODM-106 Capsule A'}, {'id': 'OG008', 'title': 'Placebo', 'description': '2 placebo subjects per Arm with matched number of placebo capsules.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.7', 'spread': '3.2', 'groupId': 'OG000'}, {'value': '0.47', 'spread': '1.04', 'groupId': 'OG001'}, {'value': '1.05', 'spread': '2.88', 'groupId': 'OG002'}, {'value': '1.93', 'spread': '1.99', 'groupId': 'OG003'}, {'value': '0.8', 'spread': '1.36', 'groupId': 'OG004'}, {'value': '2.23', 'spread': '6.12', 'groupId': 'OG005'}, {'value': '0.82', 'spread': '0.68', 'groupId': 'OG006'}, {'value': '4.14', 'spread': '4.96', 'groupId': 'OG007'}, {'value': '1.01', 'spread': '2.45', 'groupId': 'OG008'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Predose and 1, 2, 3,4, 6 and 8 hours post dose at each dose level.', 'description': 'Growth hormone levels (Cmax) in serum after single oral dosing with either ODM-106 Capsule B, ODM-106 Capsule A or placebo.', 'unitOfMeasure': 'ng/ml', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Only timepoints 2 - 6h evaluated.'}, {'type': 'SECONDARY', 'title': 'Sedation Scores on a Visual Analogue Scale (VAS)', 'timeFrame': 'Pre-dose and at 1, 6 and 10.5h post dose at each dose level', 'description': 'Assessment of sedation by subject', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Dexterity and Reaction Times', 'timeFrame': 'Pre-dose and at 1 and 6h post dose at each dose level', 'description': 'Selected battery of psychomotor tests', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Quantitative EEG', 'timeFrame': 'Pre-dose and at 1, 6 and 10 h post dose at each dose level', 'description': 'Quantitative analysis of EEG', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Panel 1', 'description': 'Single oral doses ODM-106 Capsule B: 2, 10, 25, 50 mg , placebo'}, {'id': 'FG001', 'title': 'Panel 2', 'description': 'Single oral doses ODM-106 Capsule B: 100, 100, 200mg. ODM-106 Capsule A 100 mg , placebo'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '9'}, {'groupId': 'FG001', 'numSubjects': '9'}]}, {'type': 'Period 1', 'achievements': [{'comment': '6 subjects ODM-106 Capsule B 2 mg and 2 subjects on placebo', 'groupId': 'FG000', 'numSubjects': '8'}, {'comment': '6 subjects ODM-106 Capsule B 100 mg (1 x 100mg) and 2 subjects on placebo', 'groupId': 'FG001', 'numSubjects': '8'}]}, {'type': 'Period 2', 'achievements': [{'comment': '6 subjects ODM-106 Capsule B 10 mg and 2 subjects on placebo', 'groupId': 'FG000', 'numSubjects': '8'}, {'comment': '6 subjects ODM-106 Capsule B 100 mg (10 x 10mg) and 2 subjects on placebo', 'groupId': 'FG001', 'numSubjects': '8'}]}, {'type': 'Period 3', 'achievements': [{'comment': '6 subjects ODM-106 Capsule B 25 mg and 2 subjects on placebo', 'groupId': 'FG000', 'numSubjects': '8'}, {'comment': '6 subjects ODM-106 Capsule B 200 mg (20 x 10mg) and 2 subjects on placebo', 'groupId': 'FG001', 'numSubjects': '8'}]}, {'type': 'Period 4', 'achievements': [{'comment': '6 subjects ODM-106 Capsule B 50 mg and 2 subjects on placebo', 'groupId': 'FG000', 'numSubjects': '8'}, {'comment': '6 subjects ODM-106 Capsule A 100 mg (10 x 10mg) and 2 subjects on placebo', 'groupId': 'FG001', 'numSubjects': '8'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '8'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}], 'recruitmentDetails': 'Healthy male volunteers were recruited', 'preAssignmentDetails': 'Screening : Male subjects were screened and following PE, vital signs, EEG, ECG and lab. assessments were randomised into the study.\n\nSixteen subjects were randomised to 2 panels of 8, each subject received 3 single doses of ODM-106 and 1 dose of placebo in a randomised crossover design.\n\nPanel 1 was completed before Panel 2 commenced dosing.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '18', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Panel 1', 'description': 'Single oral doses ODM-106 Capsule B 2, 10, 25, 50mg, placebo'}, {'id': 'BG001', 'title': 'Panel 2', 'description': 'Single oral doses ODM-106 Capsule B 100, 100, 200 mg. ODM-106 Capsule A 100mg, placebo'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '9', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '18', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Gender', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '9', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '18', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'Germany', 'categories': [{'measurements': [{'value': '9', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '18', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'BASIC_SCIENCE', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 16}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-03'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-03', 'completionDateStruct': {'date': '2016-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-10-28', 'studyFirstSubmitDate': '2015-03-06', 'resultsFirstSubmitDate': '2016-10-28', 'studyFirstSubmitQcDate': '2015-03-13', 'lastUpdatePostDateStruct': {'date': '2016-12-23', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2016-10-28', 'studyFirstPostDateStruct': {'date': '2015-03-20', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2016-12-23', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability.', 'timeFrame': 'From screening up to 16 weeks', 'description': 'Clinically relevant changes from baseline in safety laboratory assessments (haematology, clinical chemistry, urinalysis), vital signs (pulse and heart rate), 12 lead electrocardiograms, Holter electrocardiograms, telemetry, physical examination.'}], 'secondaryOutcomes': [{'measure': 'Peak Plasma Concentration (cMax) of ODM-106', 'timeFrame': 'Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.', 'description': 'cMax of ODM-106 after single dosing of either Capsule B or Capsule A'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve (AUC) of ODM-106', 'timeFrame': 'Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine sampling, pre-dose and for 24 hours post dose at each dose level', 'description': 'AUC of ODM-106 after single oral dosing of either Capsule B or Capsule A.'}, {'measure': 'Time to Peak Plasma Concentration (Tmax) of ODM-106', 'timeFrame': 'Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level', 'description': 'tmax of ODM-106 after single oral dosing of Capsule B or Capsule A'}, {'measure': 'Elimination Half-life of ODM-106', 'timeFrame': 'Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.', 'description': 'Elimination half-life of ODM-106 after single dosing of either Capsule B or Capsule A'}, {'measure': 'Metabolite Screening in Plasma and Urine', 'timeFrame': 'Plasma samples at pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine samples, pre-dose and for 24 hours post dose at each dose level', 'description': 'Metabolite screening in plasma and urine after single dosing'}, {'measure': 'Effect of ODM-106 on Growth Hormone Levels', 'timeFrame': 'Predose and 1, 2, 3,4, 6 and 8 hours post dose at each dose level.', 'description': 'Growth hormone levels (Cmax) in serum after single oral dosing with either ODM-106 Capsule B, ODM-106 Capsule A or placebo.'}, {'measure': 'Sedation Scores on a Visual Analogue Scale (VAS)', 'timeFrame': 'Pre-dose and at 1, 6 and 10.5h post dose at each dose level', 'description': 'Assessment of sedation by subject'}, {'measure': 'Dexterity and Reaction Times', 'timeFrame': 'Pre-dose and at 1 and 6h post dose at each dose level', 'description': 'Selected battery of psychomotor tests'}, {'measure': 'Quantitative EEG', 'timeFrame': 'Pre-dose and at 1, 6 and 10 h post dose at each dose level', 'description': 'Quantitative analysis of EEG'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'conditions': ['Healthy Volunteer Study']}, 'descriptionModule': {'briefSummary': 'The study is a dose escalation study with 8 planned dose levels. The study is a 4-period crossover design where each healthy volunteer will be randomised to receive three dose levels of ODM-106 (single doses) and one dose of placebo. The study will look at the pharmacokinetics (how the body handles the drug) and pharmacodynamics (how the drug affects the body) of ODM-106.', 'detailedDescription': 'Eight planned dose levels of ODM-106 will be compared with placebo.There will be 2 panels of subjects with 4 dose levels in each panel. Subjects will be randomised to receive 3 dose levels of active treatment (single doses) and 1 dose of placebo. The dose levels will be escalated from the smallest dose upwards within the study and within the study subject. A third panel of 8 subjects may be included to investigate further dose levels of ODM-106, investigate the effect of taking ODM-106 with food or to compare two different formulations of ODM-106. For an individual subject, the study will consist of a screening period (maximum 4 weeks), 4 study treatment periods with a wash-out period between each study treatment administration and a post-treatment period of about 2 weeks.\n\nThe study duration for an individual will be approximately 12-16 weeks. Blood samples will be collected for the assessment of the concentration of ODM-106 and its metabolite.Plasma samples and cumulative urinary samples will be collected for metabolite screening. Safety will be assessed by a 12-lead electrocardiogram (ECG), continuous ECG monitoring, Holter ECG, supine and orthostatic blood pressure and heart rate, body temperature, physical examination, electroencephalogram (EEG), laboratory safety assessments and adverse events. Sedation and psychomotor tests and a quantitative EEG will also be performed.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT'], 'maximumAge': '45 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Written informed consent obtained.\n* Participants must be able to speak, read and understand German.\n* Good general health ascertained by detailed medical history and physical examinations.\n* Males 18-45 years (inclusive).\n* Body mass index (BMI) 18-30 kg/m2 inclusive\n* Weight 55-95 kg (inclusive).\n* Participants with female partners of child-bearing potential must adhere to a proper form of contraception from first study treatment administration until 3 months after the end-of-study visit.\n\nExclusion Criteria:\n\n* A predictable poor compliance or inability to understand and comply with protocol requirements, instructions and protocol-stated restrictions or communicate well with the investigator.\n* Vulnerable subjects.\n* Veins unsuitable for repeated venipuncture.\n* Evidence of clinically relevant cardiovascular, renal, hepatic, haematological, gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator. The participants should be healthy subjects.\n* Subjects with a medical history of relevant psychiatric disorders or evidence of significant neuropsychiatric disease\n* Any condition requiring regular concomitant medication including herbal products or likely to need any concomitant medication during the study.\n* Definite or suspected personal history of hypersensitivity to drugs or excipients.\n* Intake of any medication that could affect the outcome of the study, as judged by the investigator, within 2 weeks before first study treatment administration (2 months for enzyme inducing drugs like rifampicin or carbamazepin), or less than 5 times the half-life of the medication.\n* A history of alcoholism or excess alcohol intake (including regular consumption of more than 21 units of alcohol per week) .\n* Use of nicotine-containing products within 6 months of admission and inability to refrain from using nicotine-containing products during the study.\n* History of drug abuse or positive drug screen for amphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, methamphetamine or methadone.\n* Propensity to get headache when refraining from caffeine-containing beverages.\n* Blood donation or loss of clinically relevant amount of blood within 2 months before the screening visit.\n* Abnormal 12-lead ECG finding of clinical relevance at the screening visit\n* Heart rate (HR) \\< 50 bpm or \\> 90 bpm after 10 min in rest (supine) at the screening visit\n* At the screening visit: systolic BP \\< 90 mmHg or \\> 140 mmHg, diastolic BP \\< 50 mmHg or \\> 90 mmHg, orthostatic hypotension decrease of greater than or equal to 20 mmHg for systolic BP, decrease of greater than or equal to 10 mmHg for diastolic BP.\n* Abnormal 24-h Holter of clinical relevance at the screening visit,\n* Positive serology to human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies.\n* Any abnormal value of laboratory, vital signs, or physical examination, which may in the opinion of the investigator interfere with the interpretation of the test results or cause a health risk for the subject if he takes part in the study.\n* Participation in an investigational drug study within 2 months before entry into this study.\n* An employee, a direct or indirect relative of the employee of the contract research organisation or the sponsor.\n* Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the subject.\n* Subject with abnormal standard EEG judged as clinically relevant by the investigator at screening.'}, 'identificationModule': {'nctId': 'NCT02393950', 'acronym': 'FIMPAM', 'briefTitle': 'Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers', 'organization': {'class': 'INDUSTRY', 'fullName': 'Orion Corporation, Orion Pharma'}, 'officialTitle': 'Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Escalating Doses of ODM-106: A Randomised, Double-blind, Placebo-controlled Single Centre Study in Healthy Males', 'orgStudyIdInfo': {'id': '3117001'}, 'secondaryIdInfos': [{'id': '2014-001317-33', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Drug: ODM-106', 'description': 'Oral capsules dosage 2-800mg once daily for one day', 'interventionNames': ['Drug: ODM-106']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Drug: Placebo', 'description': 'Oral capsules given once daily for one day', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'ODM-106', 'type': 'DRUG', 'description': 'Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.', 'armGroupLabels': ['Drug: ODM-106']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.', 'armGroupLabels': ['Drug: Placebo']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Berlin', 'country': 'Germany', 'facility': 'Parexel International GmbH', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}], 'overallOfficials': [{'name': 'Rainard Fuhr, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Parexel International GmbH, Berlin, Germany'}, {'name': 'John Whiteside', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Orion Corporation, Orion Pharma'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Orion Corporation, Orion Pharma', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}